Kristiana Neff, MD
Ophthalmology · Ladson, SCNPI 1174680409
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,900 of the $23,389 with a category attached, or 63.7%. Sun Pharmaceutical Industries Inc. accounts for 61.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $7,954 and has fallen 82.4% since, to $1,397 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $72.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$14K
- Kala Pharmaceuticals, Inc.$2K
- Alcon$2K
- Biotissue Holdings Inc.$967
- Ocular Therapeutix, Inc.$674
- Oyster Point Pharma, Inc.$486
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$14,90064%
- Travel & lodging$1471%
- Food & beverage$8,32336%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 73 | $14,281 |
| Kala Pharmaceuticals, Inc. | 22 | $2,470 |
| Alcon | 51 | $2,069 |
| Biotissue Holdings Inc. | 17 | $967 |
| Ocular Therapeutix, Inc. | 31 | $674 |
| Oyster Point Pharma, Inc. | 16 | $486 |
| Novartis | 18 | $327 |
| Bausch & Lomb Americas Inc. | 13 | $289 |
| AbbVie(2 entities) | 15 | $283 |
| Glaukos Corporation | 5 | $262 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $174 |
| Harrow Eye, LLC | 6 | $152 |
| Dompe US, Inc. | 6 | $122 |
| Shire North American Group Inc | 6 | $114 |
| Aerie Pharmaceuticals, Inc. | 7 | $109 |
| Tarsus Pharmaceuticals, Inc. | 5 | $95 |
| Avedro Inc. | 1 | $77 |
| Eyevance Pharmaceuticals LLC | 4 | $76 |
| Rayner Intraocular Lenses Limited | 4 | $76 |
| NEW World Medical,inc. | 2 | $63 |
| Omeros Corporation | 4 | $49 |
| Amgen(2 entities) | 2 | $44 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $32 |
| Rxsight Inc | 1 | $24 |
| Akorn, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Spinal Simplicity, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$7,022
- BROMSITE$6,122
- EYSUVIS$2,000
- Clareon$287
- AcrySof$279
- KXL System$153
- Photrexa$153
- ORA$139
- AcrySof IQ VIVITY IOL$127
- Rocklatan$126
- SIMBRINZA$126
- Rhopressa$126
- DEXTENZA$122
- Prokera$119
- AcrySof IQ PanOptix$118
How this compares
$23,389 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 93 | $106,805 |
| XiidraLifitegrast | 47 | $57,370 |
| MieboPerfluorohexyloctane/Pf | 60 | $48,877 |
| Cyclosporine | 50 | $29,626 |
| TyrvayaVarenicline Tartrate | 27 | $24,418 |
| LotemaxLoteprednol Etabonate | 53 | $18,917 |
| CequaCyclosporine | 26 | $18,026 |
| Prednisolone Acetate | 380 | $16,934 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $14,638 |
| LumiganBimatoprost | 24 | $11,578 |
| Loteprednol Etabonate | 77 | $11,543 |
| Alphagan PBrimonidine Tartrate | 21 | $7,808 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $5,898 |
| RhopressaNetarsudil Mesylate | 17 | $5,479 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $4,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $283 | $140,830174 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $289 | $106,247107 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate, Lotemax Sm | $32 | $34,115143 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $486 | $24,41827 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $14,281 | $18,02626 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $109 | $10,43231 claims |
| AlconSimbrinza | $2,069 | $5,89824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Ladson
- David VromanLadson$61K
- Millin BudevLadson$16K
- John ThompsonLadson$13K
- Rachel EllynLadson$11K
- Phelan PiehotaLadson$10K
- Michelle YingLadson$7K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.